Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Friday, December 11, 2026		
Satellite Symposia: MDS in Practice: Navigating Complex Decisions Across the Disease Spectrum	Chair: Jacqueline Garcia, MD	7:00 - 10:00 a.m. MCCNO - 208-210
Satellite Symposia: Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together	Pedro Vianna, MD	11:00 a.m. - 2:00 p.m. MCCNO - Hall C
Satellite Symposia: Bispecific Antibodies in Action: Applying Evidence Across the DLBCL and FL Care Continuum	Jennifer Crombie, MD	11:00 a.m. - 2:00 p.m. MCCNO - R02-R05
Satellite Symposia: CAR T-Cell Agent Integration in Lymphoma: A Masterclass for Real-World Implementation	Caron Jacobson, MD, MMSc	11:00 a.m. - 2:00 p.m. MCCNO - 243-245
Satellite Symposia: Cases and Conversations: Precision Care in BPDCN-Integrating Updated Diagnostic Pathways With Current and Emerging CD123-Directed Therapies	Andrew Lane, MD, PhD	11:00 a.m. - 2:00 p.m. MCCNO - La Nouvelle A-B
Satellite Symposia: The CELMoD Shift: Translating Protein Degradation Science into Practice-Changing Myeloma Care	Chair: Paul Richardson, MD	11:00 a.m. - 2:00 p.m. MCCNO - 217-219
Satellite Symposia: Decoding High-Risk AML: Applying Molecular Insights to Clinical Decision-Making	Chair: Richard Stone, MD	11:00 a.m. - 2:00 p.m. MCCNO - 343-345
Satellite Symposia: Mastering Systemic Mastocytosis: Diagnostic Criteria, Risk Stratification, and Patient-Centered Treatment Across Indolent and Advanced Disease	Chair: Daniel DeAngelo, MD, PhD	11:00 a.m. - 2:00 p.m. MCCNO - 265-268

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Friday, December 11, 2026		
Satellite Symposia: Realigning Modern Care in MCL: Guidance on the Next Wave of Advances With BTK Inhibitor Options and New Targeted Strategies	Christine Ryan, MD	11:00 a.m. - 2:00 p.m. Hilton - Grand Ballroom AB
Trainee Activities and Services: Blood Buddies: Medical Education	Mark Sorial, PharmD	1:35 - 3:55 p.m. Generations Hall - Upper Level
Satellite Symposia: FAST Track to Enhanced CLL Outcomes: Finite Therapy Advances With BTK Inhibitors as New Standards for Frontline Treatment	Chair: Matthew Davids, MD, MMSc	3:00 - 6:00 p.m. Hilton - Grand Ballroom CD
Scientific Workshop on Clonal Evolution in Chronic Lymphocytic Leukemia: Mechanisms of Resistance, Disease Progression and Measurable Residual Disease-Based Monitoring	Co-Chair: Paolo Ghia, MD, PhD	3:00 - 6:00 p.m. MCCNO - 288-290
Scientific Workshop: Translating Spatial Biology into the Diagnostic Lab- Spatial Proteomic and Transcriptomic Approaches for the Evaluation of Lymphoma	Scott Rodig, MD, PhD	3:03 - 3:43 p.m. MCCNO - 252-254
Scientific Workshop: Molecular Mechanisms of Resistance to Targeted Agents - Genetic Mechanisms of Resistance to Non-Covalent BTK Inhibitors	Jennifer Brown, MD, PhD	3:05 - 4:00 p.m. MCCNO - 288-290
Scientific Workshop: Risk Factors of Clonal Hematopoiesis - Age-Related CH	Christopher Reilly, MD	3:05 - 3:55 p.m. MCCNO - 271-273
Scientific Workshop: Identifying Biological Vulnerabilities in TP53 mutations	Moderator: Lachelle Weeks, MD, PhD	4:00 - 4:50 p.m. MCCNO - 271-273

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Friday, December 11, 2026		
Scientific Workshop: Novel Approaches in Molecular Diagnostics - Rapid Long-Read Sequencing for Acute Leukemia Diagnosis	Gabriel Griffin, MD	4:38 - 5:18 p.m. MCCNO - 252-254
Scientific Workshop: MRD Assessment as a Tool for Detecting and Monitoring Clonal Evolution-Multidimensional Analysis of MRD	Catherine Wu, MD	5:00 - 5:55 p.m. MCCNO - 288-290
Satellite Symposia: Overcoming the Challenges of Managing Adolescents and Young Adults With Ph-Negative Acute Lymphoblastic Leukemia	Marlise Luskin, MD, MSCE	7:00 - 10:00 p.m. MCCNO - 343-345
Saturday, December 12, 2026		
Meet the Journal Editors: Blood Immunology & Cellular Therapy	Caron Jacobson, MD, MMSc	9:05 - 9:30 a.m. MCCNO - Hall F Journals Studio
103: Preliminary safety and efficacy of glofitamab monotherapy and glofitamab in combination with polatuzumab vedotin in patients with Richter's transformation (RT)	Christine Ryan, MD	9:30 - 9:45 a.m. MCCNO - 260-262
Education Program: Navigating the Treatment Landscape of CNS Lymphomas - The Role of CAR T-Cell Therapy, Novel Targeted Agents, and Emerging Therapies in CNS Lymphomas	Lakshmi Nayak, MD	9:30 - 10:45 a.m. MCCNO - 278-282
Scientific Program: Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward	Chair: Giada Bianchi, MD	9:30 - 10:45 a.m. MCCNO - 288-290

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
Scientific Program: Back to the Future: Using Old and New Tools to Move the Field of Plasma Cell Research Forward- Show Me Your Face and I Will Understand Your Purpose: How Protein Structure Informs Function	Xin Gu, PhD	9:30 - 10:45 a.m. MCCNO - 288-290
154: Randomized controlled trial of a psychosocial digital application (THRIVE-MM) for patients living with multiple myeloma	Hermioni Amonoo, MD, MPP, MPH	10:15 - 10:30 a.m. MCCNO - La Nouvelle C
Trainee Activities and Services: Career Development Lunch- International Graduate Hematology	Nikhil Munshi, MD	11:15 a.m. - 12:15 p.m. Hilton - St. Charles Ballroom
Trainee Activities and Services: Career Development Lunch- Medical and Bio Informatics and AI	Andrew Hantel, MD, MPH	11:15 a.m. - 12:15 p.m. Hilton - St. Charles Ballroom
Trainee Activities and Services: Career Development Lunch- Women in Hematology	Jennifer Crombie, MD	11:15 a.m. - 12:15 p.m. Hilton - St. Charles Ballroom
166: A phase 2 trial of rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results from initial and expansion cohorts	Reid Merryman, MD	12:45 - 1:00 p.m. MCCNO - 278-282
253: Safety and efficacy of surovatamig, a novel, fully human, IgG4, CD19xCD3 bispecific T-cell engager (TCE), in patients (pts) with relapsed/ refractory (R/R) chronic lymphocytic leukemia/ small lymphocytic lymphoma (CLL/SLL)	Matthew Davids, MD, MMSc	2:00 - 2:15 p.m. MCCNO - 271-273

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
Education Program: Classical Hematology: Innovation and Technology to Match Supply and Demand - Dealing with Workforce Challenges in Classical Hematology	Robert Stern, MD	2:00 - 3:15 p.m. MCCNO - 293-294
Scientific Symposia: Single-Cell and Spatial Genomics Redefining the Immune Cell Landscape in AML/MDS	Chair: Catherine Wu, MD	2:00 - 3:15 p.m. MCCNO - 288-290
284: IL-7/IL-7Rα reprogramming primes sting signaling in CAR-NK cells and unlocks coordinated innate-adaptive antitumor immunity	Andreia Maia, MS, PhD	2:15 - 2:30 p.m. MCCNO - 353-355
285: CAR-stick enables localized interleukin-12 delivery to enhance CD70 CAR-NK cell therapy for acute myeloid leukemia	Remy Dulery, MD, PhD	2:30 - 2:45 p.m. MCCNO - 353-355
239: Chemotherapy exposure is associated with genome wide somatic events and ultra-high risk double-hit TP53 alterations that impact cancer specific survival in previously treated Waldenström's macroglobulinemia	Nickolas Tsakmaklis	3:00 - 3:15 p.m. MCCNO - New Orleans Theatre A
290: Low actual body weight-to-ideal body weight ratio is associated with adverse outcomes following ideal body weight-based dosing post-transplant cyclophosphamide in allogeneic hematopoietic cell transplantation	Nuttavut Sumransub, MD	3:15 - 3:30 p.m. MCCNO - 388-390
Blood Journals Club: Characteristics of Donor and Recipient Clonal Hematopoiesis in Non-myeloablative Transplant for Sickle Cell Disease	Lachelle Weeks, MD, PhD	3:30 - 4:30 p.m. MCCNO - Hall F Journals Studio

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Saturday, December 12, 2026		
355: Mediator complex tail module subunit MED24 is a selective dependency in acute myeloid leukemia	Ran Xu, PhD	4:00 - 4:15 p.m. MCCNO - R02-R05
440: HLA class I peptide-binding motif mismatch status is a predictor of cytokine release syndrome in haploidentical and mismatched donor transplantation with post-transplant cyclophosphamide	Nuttavut Sumransub, MD	4:15 - 4:30 p.m. MCCNO - 388-390
460: Receipt of "ideal" quality end-of-life care among adults with blood cancers aged 18 to 64 years	Hari Raman, MD, MBA	4:45 - 5:00 p.m. MCCNO - 260-262
Sunday, December 13, 2026		
493: B-IPSS: An internationally validated prognostic scoring system for BPDCN	Shai Shimony, MD, MPH	9:30 - 9:45 a.m. MCCNO - Hall B
499: Real-time epigenomic classification of acute leukemias demonstrates feasibility and concordance in clinical practice	Evan Chen, MD	9:30 - 9:45 a.m. MCCNO - Great Hall BC
536: Fixed-duration acalabrutinib-venetoclax ± obinutuzumab sustains survival and delays retreatment versus chemoimmunotherapy at 5 years in treatment-naive chronic lymphocytic leukemia (AMPLIFY)	Jennifer Brown, MD, PhD	9:45 - 10:00 a.m. MCCNO - New Orleans Theatre A
548: Integrated DNA and RNA profiling reveals genomic instability as the hallmark of high-risk multiple myeloma beyond ims/IMWG consensus genomic staging	Anil Aktas-Samur, PhD	9:45 - 10:00 a.m. MCCNO - La Nouvelle C

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Sunday, December 13, 2026		
549: Genomic landscape and clonal evolution of treatment response in smoldering multiple myeloma	Rosa Toenges, MD	10:00 - 10:15 a.m. MCCNO - La Nouvelle C
508: The inhibitor of BTK (IBTK?) plays a distinct, BTK-independent signaling role in MYD88-mutated lymphomas	Amanda Kofides, MSc	10:15 - 10:30 a.m. MCCNO - 275-27
539: Six-year follow-up results of a multicenter, Phase 2 study of minimal residual disease (MRD)-guided acalabrutinib, venetoclax, obinutuzumab (AVO) in a population of previously untreated patients with CLL enriched for high-risk disease	Christine Ryan, MD	10:30 - 10:45 a.m. MCCNO - New Orleans Theatre A
540: Acalabrutinib plus venetoclax vs venetoclax plus obinutuzumab in patients with previously untreated chronic lymphocytic leukemia: Interim results from the randomized, global, phase 3 MAJIC study	Matthew Davids, MD, MMSc	10:45 - 11:00 a.m. MCCNO - New Orleans Theatre A
Special-Interest Session: Treating Fairly Rounds Lunch- Challenges and Opportunities with Healthcare Reform	Amar Kelkar, MD, MPH	11:30 a.m. - 12:30 p.m. Marriott Warehouse - Gravier AB
732: A pilot randomized controlled trial of a fear of cancer recurrence intervention for lymphoma survivors	Miryam Yusufov, PhD	5:45 - 6:00 p.m. MCCNO - 278-282

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Monday, December 14, 2026		
Marquee Session: E. Donnall Thomas Lecture and Prize- Leveraging the Biology of the MLL (KMT2A) Complex to Discover New Therapies for Leukemia	Recipient: Scott Armstrong, MD, PhD	9:00 - 10:00 a.m. MCCNO - Hall E
818: Transcriptional rewiring through regional haploinsufficiency defines del(1p32) multiple myeloma	Hanne Marie Liddle Norseth, MD	10:45 - 11:00 a.m. MCCNO - La Nouvelle A-B
783: Phase 2 trial of loncastuximab tesirine (WM-NET1 trial) in patients with relapsed/refractory and high-risk Waldenström macroglobulinemia	Shayna Sarosiek, MD	11:00 - 11:15 a.m. MCCNO - New Orleans Theatre B
844: Access-driven timing of CD38 monoclonal antibody therapy and survival in multiple myeloma: A multinational analysis of 9,112 patients from the Asia-Pacific and Australia-New Zealand myeloma and related diseases registry	Ji Hyun Lee, MD, PhD	11:15 - 11:30 a.m. MCCNO - La Nouvelle C
828: Interim analysis of a phase 1/2, open label study to evaluate safety, tolerability, and efficacy of elranatamab in patients with relapsed AL amyloidosis	Shahrier Hossain, PharmD	11:45 a.m. - 12:00 p.m. MCCNO - 260-262
Scientific Spotlight Session: CAR-T Manufacturing Across Nations: From Low-to-Middle-Income Academic Platforms to Frontier Innovations in Global Access	Co-Chair & Presenter: Sarah Nikiforow, MD, PhD	2:45 - 04:00 p.m. MCCNO - 391-392
935: A bone marrow single cell atlas defines conserved immune aging and remodeling from precursor disease to relapsed multiple myeloma	Joshua Rivera, PhD	3:45 - 4:00 p.m. MCCNO - La Nouvelle A-B

Dana-Farber Cancer Institute

Oral Presentations at ASH Annual Meeting

Note: All times listed are Central Time. Schedule and locations subject to change by ASH.

PRESENTATION	SPEAKER	TIME/LOCATION
Monday, December 14, 2026		
Education Program: A Decade of Progress Towards Safer and More Broadly Applicable Allogeneic Stem Cell Transplantation- Targeting Acute and Chronic GVHD with Effective New Therapies	Mahasweta Gooptu, MD	4:30 - 5:45 p.m. MCCNO - 343-345
1041: Dual BCMA/FcRL5 targeting with an AI-designed trite surpasses BCMA-directed therapy in multiple myeloma	Jessica Encinas Mayoral, PhD	5:00 - 5:15 p.m. MCCNO - La Nouvelle C
1047: Tumor burden-dependent APRIL depletion undermines durable immunity in myeloma precursors and is reversed by BCMA-directed therapy	Noé Perron, PhD	5:00 - 5:15 p.m. MCCNO - La Nouvelle A-B
1065: Single-cell genotyping and methylomics resolves clonal hierarchies and epiclonal heterogeneity in normal and malignant hematopoiesis	Kyung Lock Kim, PhD	5:00 - 5:15 p.m. MCCNO - 393-396
1044: Integrated functional genomics identify mechanisms of response and resistance to RAS inhibition in multiple myeloma	Torsten Steinbrunn, MD, PhD	5:45 - 6:00 p.m. MCCNO - La Nouvelle C
Tuesday, December 15, 2026		
Marquee Session: Late-Breaking Abstracts Session	Co-Chair: Maureen Achebe, MD, MPH	7:30 - 9:00 a.m. MCCNO - Hall E
Marquee Session: Janet Rowley Basic Science Medal	Recipient: Benjamin Ebert, MD, PhD	9:30 - 9:45 a.m. MCCNO - Hall E